The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12

被引：0

作者：

Dignass, A. ^{[1
]}

Rubin, D. ^{[2
]}

Bressler, B. ^{[3
]}

Huang, K. H. ^{[4
]}

Shipitofsky, N. ^{[4
]}

Germinaro, M. ^{[4
]}

Zhang, H. ^{[4
]}

Johanns, J. ^{[4
]}

Feagan, B. ^{[5
]}

Sandborn, W. ^{[6
]}

Sands, B. ^{[7
]}

Hisamatsu, T. ^{[8
]}

Lichtenstein, G. ^{[9
]}

Panes, J. ^{[10
]}

Allegretti, J. ^{[11
]}

机构：

[1] Agaples Markus Hosp, Dept Med, Frankfurt, Germany

[2] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA

[3] Univ British Columbia, Div Gastroenterol, Vancouver, BC, Canada

[4] Janssen Res & Dev LLC, Immunol, Spring House, PA USA

[5] Western Univ, Robarts Clin Trials, London, ON, Canada

[6] Univ Calif San Diego, Div Gastroenterol, La Jolla, CA USA

[7] Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, New York, NY 10029 USA

[8] Kyorin Univ, Dept Gastroenterol & Hepatol, Tokyo, Japan

[9] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA

[10] Hosp Clin Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

[11] Brigham & Womens Hosp, Crohns & Colitis Ctr, Div Gastroenterol Hepatol & Endoscopy, 75 Francis St, Boston, MA 02115 USA

来源：

JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OP23

引用

页码：I025 / I026

页数：3

共 50 条

[1] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 213 QUASAR STUDY RESULTS THROUGH WEEK 12
Allegretti, Jessica R.
Rubin, David T.
Bressler, Brian
Huang, Kuan-Hsiang G.
Shipitofsky, Nicole
Germinaro, Matthew
Zhang, Hongyan
Johanns, Jewel
Feagan, Brian
Sandborn, William J.
Sands, Bruce E.
Hisamatsu, Tadakazu
Lichi, Gary R.
Lichtenstein, Gary R.
Panes, Julian
Dignass, Axel
GASTROENTEROLOGY, 2022, 162 (07) : S963 - S964
[2] The Effect of Guselkumab Induction Therapy on Inflammatory Biomarkers in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results Through Week 12
Lichtenstein, Gary
Dignass, Axel
Sandborn, William J.
Huang, Kuan-Hsiang
Germinaro, Matthew
Wilson, Rebbecca
Zhang, Hongyan
Chen, Baili
Chen, Minhu
Hisamatsu, Tadakazu
Feagan, Brian G.
Panes, Julian
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S587 - S587
[3] Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
Peyrin-Biroulet, Laurent
Allegretti, Jessica R.
Rubin, David T.
Bressler, Brian
Germinaro, Matthew
Huang, Kuan-Hsiang
Shipitofsky, Nicole
Zhang, Hongyan
Wilson, Rebbecca
Han, Chenglong
Feagan, Brian G.
Sandborn, William J.
Panes, Julian
Hisamatsu, Tadakazu
Lichtenstein, Gary R.
Sands, Bruce E.
Dignass, Axel
GASTROENTEROLOGY, 2023, 165 (06) : 1443 - 1457
[4] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
Allegretti, Jessica R.
Peyrin-Biroulet, Laurent
Feagan, Brian G.
Bressler, Brian
Lichtenstein, Gary R.
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Shipitofsky, Nicole
Jiang, Lingjing
Zhang, Hongyan
Hisamatsu, Tadakazu
Panes, Julian
Dignass, Axel
Sands, Bruce E.
Rubin, David T.
GASTROENTEROLOGY, 2023, 164 (06) : S1572 - S1572
[5] The Effect of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results at Week 12 by Prior Inadequate Response or Intolerance to Advanced
Rubin, David T.
Allegretti, Jessica R.
Sands, Bruce E.
Huang, Kuan-Hsiang
Kavalam, Mary
Germinaro, Matthew
Wilson, Rebbecca
Zhang, Hongyan
Mihaly, Emese
Hisamatsu, Tadakazu
Dignass, Axel
Panes, Julian
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S500 - S501
[6] The Efficacy of Induction Treatment With Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Induction Study Results at Week 12 by Prior Advanced Therapy History
Bressler, Brian
Peyrin-Biroulet, Laurent
Allegretti, Jessica R.
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Shipitofsky, Nicole
Miao, Ye
Zhang, Hongyan
Bortlik, Martin
Hlavaty, Tibor
Fujii, Toshimitsu
Feagan, Brian G.
Sands, Bruce E.
Dignass, Axel
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S806 - S807
[7] EFFICACY AND SAFETY OF COMBINATION INDUCTION THERAPY WITH GUSELKUMAB AND GOLIMUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS THROUGH WEEK 12 OF THE PHASE 2A VEGA STUDY
Feagan, Brian G.
Sands, Bruce E.
Sandborn, William J.
Shipitofsky, Nicole
Marko, Melissa G.
Sheng, Shihong
Johanns, Jewel
Germinaro, Matthew
Vetter, Marion
Panes, Julian
GASTROENTEROLOGY, 2022, 162 (07) : S215 - S216
[8] GUSELKUMAB IMPROVES SYMPTOMS OF FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12
Dignass, Axel
Panes, Julian
Rubin, David T.
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Pandya, Dwiti
Han, Chenglong
Miao, Ye
Zhang, Hongyan
Gu, Fang
Rowbotham, David S.
Mihaly, Emese
Bressler, Brian
Lichtenstein, Gary R.
Allegretti, Jessica R.
GASTROENTEROLOGY, 2024, 166 (05) : S848 - S849
[9] Guselkumab improves symptoms of fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study results at Week 12
Dignass, A.
Panes, J.
Rubin, D. T.
Huang, K. H. G.
Germinaro, M.
Pandya, D.
Han, C.
Miao, Y.
Zhang, H.
Gu, F.
Rowbotham, D.
Mihaly, E.
Bressler, B.
Lichtenstein, G. R.
Allegretti, J. R.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I165 - I166
[10] Cumulative response to guselkumab through week 24 of induction in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
Rubin, D.
Sands, B.
Lichtenstein, G.
Baker, T.
Huang, K. H.
Germinaro, M.
Miao, Y.
Zhang, H.
Nancey, S.
Allegretti, J.
Feagan, B.
Hisamatsu, T.
Panes, J.
Dignass, A.
Bressler, B.
Peyrin-Biroulet, L.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1722 - I1723

← 1 2 3 4 5 →